Delayed Pembrolizumab-Associated Sarcoidosis
- PMID: 38976531
- DOI: 10.1097/MJT.0000000000001674
Delayed Pembrolizumab-Associated Sarcoidosis
Conflict of interest statement
The authors have no conflicts of interest to declare.
References
-
- Johnson DB, Chandra S, Sosman JA. Immune checkpoint inhibitor toxicity in 2018. JAMA. 2018;320:1702–1703.
-
- Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375–2391.
-
- Muntyanu A, Netchiporouk E, Gerstein W, et al. Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management. J Cutan Med Surg. 2021;25:59–76.
-
- Goldinger SM, Stieger P, Meier B, et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res. 2016;22:4023–4029.
-
- Cornejo CM, Haun P, English J, et al. Immune checkpoint inhibitors and the development of granulomatous reactions. J Am Acad Dermatol. 2019;81:1165–1175.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical